

PHARMESIS INTERNATIONAL LTD.
(the “**Company**”)
(Incorporated in the Republic of Singapore)
(Company Registration Number: 200309641E)

**COMPLETION OF SUBSCRIPTION OF AN AGGREGATE OF 4,600,000 NEW ORDINARY SHARES
IN THE CAPITAL OF THE COMPANY**

Further to the announcements made by the Company on 20 March 2023 and 28 March 2023 in relation to the proposed subscription by Yu Yi-Wen (“**YYW**”) and Zheng Haoyuan (“**ZHY**”) of an aggregate of 4,600,000 new ordinary shares in the capital of the Company (“**Subscription**”), the Board of Directors wishes to announce that the Subscription was completed on 5 April 2023 (“**Completion Date**”), pursuant to which an aggregate of 4,600,000 new ordinary shares (“**Subscription Shares**”) were issued and allotted to YYW and ZHY pursuant to the terms and conditions of the subscription agreements dated 20 March 2023. Following the completion of the Subscription, the issued and paid-up share capital of the Company has increased to 27,600,000 shares.

The Subscription Shares will, rank *pari passu* in all respects with and carry all rights similar to with all existing shares of the Company in issue on the day immediately prior to the date on which the Subscription Shares are issued, except that they will not rank for any dividend, right, allotment or other distribution, the record date for which falls on or before Completion Date.

The Subscription Shares will be listed and quoted on the official list of the Singapore Exchange Securities Trading Limited with effect from 9:00 a.m on 10 April 2023.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer
5 April 2023